🇺🇸 FDA
Pipeline program

MB-102 DMID

HDNP102-301

Phase 3 small_molecule completed

Quick answer

MB-102 DMID for Kidney Diseases is a Phase 3 program (small_molecule) at Hangzhou Zhongmei Huadong Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).

Program details

Company
Hangzhou Zhongmei Huadong Pharmaceutical Co.,
Indication
Kidney Diseases
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials